title: [Clinical study of fuzheng jiangnian capsule in improving pre-thrombosis correlated factors in patients with coronary heart disease].
abstract: OBJECTIVE
  To explore the effect of Fuzheng Jiangnian Capsule (FZJN) on the pre-thrombosis correlated factors in patients with coronary heart disease (CHD).
  
  
  METHODS
  Ninety patients with CHD complicated with blood hyperviscosity syndrome were treated with conventional treatment and randomly divided into three groups by the additional treatment, i. e. the FZJN group (FZJN, a preparation with action of invigorating Pi, supplementing Shen, and activating blood circulation), the CSDP group [Compound Salviae droplet pill, CSDP) with the action of activating blood circulation to remove blood stasis) and the aspirin (ASP) group, 30 patients in each group. After two months of treatment, clinical efficacy, the levels of endothelin (ET), nitric oxide (NO), coagulation factor I (Fib), D-dimer (DD), thrombocytic granule membranous glucoprotein (CD62p), superoxide dismutase (SOD), high- and low-density lipoprotein-cholesterol (HDL-C, LDL-C) in patients before and after treatment were observed and compared with those in the healthy control group.
  
  
  RESULTS
  Compared with the healthy control group, the levels of Fib, DD, ET, CD62p were significantly higher, NO and SOD significantly lower (P<0.05, P<0.01) in all the patients with CHD. Compared with the same group before treatment, the levels of Fib, DD, ET, CD62p, LDL-C in the FZJN group lowered significantly, while NO and SOD raised significantly (P <0.05, P <0.01). ET and CD62p in the CSDP group lowered significantly, while SOD raised significantly (P < 0.05), CD62p in the ASP group lowered significantly (P < 0.05). No statistical difference was found in comparison of DD or ET, though certain improvement was shown. The total effective rate in relieving TCM syndromes and angina pectoris, and the decrease or stop rate of nitrate esters medication were superior in FZJN group to those in the CSDP group and the ASP group, respectively (P <0.05). The rate of electrocardiogram improvement in the FZJN and CSDP group was superior to that in the ASP group (P< 0.05).
  
  
  CONCLUSIONS
  Increase of Fib, DD, ET, CD62p, and decrease of NO and SOD levels were found in patients with CHD in prethrombosis stage. Compared with ASP, compound Chinese medicinal herbs can act on the prethrombosis manner of CHD patients through multi-paths, multi-links. FZJN showed better efficacy in improving correlated blood molecule markers and clinical syndromes than CSDP, suggesting that the possible mechanism of FZJN might be related to its actions in dilating blood vessels, improving microcirculation, alleviating endothelial cell damage, inhibiting activity of blood platelet, regulating coagulation-fibrolysis balance, improving metabolism of free radicals as well as lowering the level of LDL-C.
authors.affiliation: Hospital, Shandong University, Jinan. sijia20032004@sina.com
authors.forename: Lu-Yang
authors.initials: LY
authors.lastname: Li
authors.forename: Guo-Hua
authors.initials: GH
authors.lastname: Ren
authors.forename: Xiang-Hong
authors.initials: XH
authors.lastname: Liu
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy; D001809:Blood Viscosity; D002214:Capsules; D003327:Coronary Disease / Q000188:drug therapy*; D003328:Coronary Thrombosis / Q000517:prevention & control*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008516:Medicine, Chinese Traditional; D008875:Middle Aged; D008517:Phytotherapy; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents